Page last updated: 2024-10-31

mianserin and Cruveilhier-Baumgarten Syndrome

mianserin has been researched along with Cruveilhier-Baumgarten Syndrome in 1 studies

Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.

Cruveilhier-Baumgarten Syndrome: Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
El-Tanbouly, DM1
Wadie, W1
Sayed, RH1

Other Studies

1 other study available for mianserin and Cruveilhier-Baumgarten Syndrome

ArticleYear
Modulation of TGF-β/Smad and ERK signaling pathways mediates the anti-fibrotic effect of mirtazapine in mice.
    Toxicology and applied pharmacology, 2017, 08-15, Volume: 329

    Topics: Animals; Antioxidants; Collagen; Glutathione; Hepatic Stellate Cells; Hypertension, Portal; Lipid Pe

2017